Ipamorelin
Growth hormone secretagogue
Ipamorelin is an experimental growth-hormone secretagogue. Small early human studies show a GH response but do not establish long-term health benefit.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
Ipamorelin is a synthetic pentapeptide GH secretagogue. The intravenous trial formulation does not establish the identity or safety of arbitrary acetate vials.
- Human research
- Limited
- Replication
- Single research group
- Clinical endpoints
- Surrogate measures
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
Measured terminal half-life
Approximately 2 hours after intravenous administration in a small study
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersHuman study1999
U.S. National Library of Medicine (PubMed)
Accessed:
Research gaps
- ·Not approved as a medicine
- ·Insufficient long-term and route-specific safety data
- ·Clinical benefit beyond experimental endpoints is unclear
Mechanism
Ipamorelin activates the ghrelin/GHSR-1a receptor and can thereby stimulate growth-hormone release from the pituitary.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersHuman study1999
U.S. National Library of Medicine (PubMed)
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·FDA describes serious adverse events in an intravenous gastric-motility study; causality cannot be established from the summary alone.
Contraindications and warnings
- ·Contraindications cannot be determined reliably from the available data.
Interactions
- ·Interactions for the research or product forms described here have not been adequately studied.
Research gaps
- ·Not approved as a medicine
- ·Insufficient long-term and route-specific safety data
- ·Clinical benefit beyond experimental endpoints is unclear
- FDA: Safety risks associated with ipamorelin in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersHuman study1999
U.S. National Library of Medicine (PubMed)
Accessed:
- FDA: Safety risks associated with ipamorelin in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed: